SU2C-CRI Cancer Immunology Translational Research Dream Team Grant Available

Share this content:

(ChemotherapyAdvisor) – The American Association for Cancer Research (AACR) is seeking Letters of Intent for a new Stand Up To Cancer (SU2C)-Cancer Research Institute (CRI) Cancer Immunology Translational Research Dream Team.

The Dream Team will receive a $6 million, three-year grant for translational cancer research projects that address laboratory and clinical efforts leading to the immunological treatment, control, and prevention of cancer. Projects should also deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators.

“Significant scientific developments in the field of cancer immunology and the recent FDA approvals of two cancer immunotherapies highlight the field's potential to transform cancer treatment,” AACR noted.

Projects may also include identification of inflammatory/immune pathways involved in cancer initiation, progression, dissemination, and responsiveness to therapy and their targeting by therapeutic approaches such as vaccines, antibodies, adoptive cell transfer, cytokines, and other molecularly targeted therapeutics.

Letters of Intent must be submitted by 12 p.m. (noon) EST on Monday, April 9, 2012. The SU2C-CRI Cancer Immunology Translational Research Dream Team is scheduled to be announced in September.

To maximize creativity, innovation, and collaboration, the Dream Team must include laboratory and clinical researchers, senior and/or young investigators and senior scientists who have not worked together in the past, as well as patient advocates. Mechanisms to foster collaboration within and among the Dream Teams should be employed, an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress.

A SU2C-CRI Joint Scientific Advisory Committee (JSAC), chaired by Nobel Laureate Phillip A. Sharp, PhD, Massachusetts Institute of Technology, will conduct a unique, interactive, rapid, and rigorous evaluation of the applications via a multistep scientific review process.

For general information on eligibility criteria, the application process, and other details about the SU2C-CRI Cancer Immunology Translational Research Dream Team, please visit: www.aacr.org/SU2CCRI. Inquiries may also be directed to the SU2C Grants Office: (267) 765-1049, or email SU2C@aacr.org.

Interested applicants should submit Letters of Intent detailing their best ideas for cancer immunology translational research using the "proposalCENTRAL" website at: https://proposalcentral.altum.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs